Terms: = Thyroid cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Prognosis
11 results:
1. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary thyroid cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract] [Full Text] [Related]
2. Construction of a ferroptosis-related eight gene signature for predicting the prognosis and immune infiltration of thyroid cancer.
Ren X; Du H; Cheng W; Wang Y; Xu Y; Yan S; Gao Y
Front Endocrinol (Lausanne); 2022; 13():997873. PubMed ID: 36407322
[TBL] [Abstract] [Full Text] [Related]
3. Identifying key genes of classic papillary thyroid cancer in women aged more than 55 years old using bioinformatics analysis.
Li CC; Ullah MHE; Lin X; Shan SK; Guo B; Zheng MH; Wang Y; Li F; Yuan LQ
Front Endocrinol (Lausanne); 2022; 13():948285. PubMed ID: 36120433
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
Front Immunol; 2022; 13():843408. PubMed ID: 35693827
[TBL] [Abstract] [Full Text] [Related]
5. Identification of key genes and miRNAs markers of papillary thyroid cancer.
Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q
Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611
[TBL] [Abstract] [Full Text] [Related]
6. Gene expression differences between thyroid carcinoma, thyroid adenoma and normal thyroid tissue.
Wang Q; Shen Y; Ye B; Hu H; Fan C; Wang T; Zheng Y; Lv J; Ma Y; Xiang M
Oncol Rep; 2018 Dec; 40(6):3359-3369. PubMed ID: 30272326
[TBL] [Abstract] [Full Text] [Related]
7. Warranting investigation of primary lung adenocarcinoma in patients with an extrapulmonary malignancy and lung nodules due to high frequency.
Zhu B; Dalal S; Kamp DW; Lin X
Am J Clin Pathol; 2014 Mar; 141(3):429-36. PubMed ID: 24515772
[TBL] [Abstract] [Full Text] [Related]
8. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract] [Full Text] [Related]
9. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract] [Full Text] [Related]
10. Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma.
Cavalheiro BG; Junqueira CR; Brandão LG
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):812-7. PubMed ID: 19687404
[TBL] [Abstract] [Full Text] [Related]
11. Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (timp-2) in medullary thyroid carcinoma: prognostic implications.
Cavalheiro BG; Junqueira CR; Brandão LG
Thyroid; 2008 Aug; 18(8):865-71. PubMed ID: 18651826
[TBL] [Abstract] [Full Text] [Related]
